US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Valion Bio Inc

0.8800

-0.0509-5.47%

Post-market: 0.89000.0100+1.14%19:59 EDT

Volume:368.57K

Turnover:353.03K

Market Cap:2.76M

PE:-0.11

High:1.06

Open:0.9700

Low:0.8546

Close:0.9309

52wk High:5.60

52wk Low:0.7217

Shares:3.14M

Float Shares:2.78M

Volume Ratio:2.01

T/O Rate:13.27%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-7.6830

EPS(LYR):-19.6785

ROE:-82.69%

ROA:-28.69%

PB:0.16

PE(LYR):-0.04

Loading ...

Overview Company News Filings

Valion Bio’s Velocity Bioworks licenses LarmorBio’s BioScan-NMR platform

Valion Bio Q1 net loss widens to $6.2 million

BRIEF-Valion Bio Reports First Quarter 2026 Financial Results

Valion Bio Q1 EPS $(2.23) Up From $(2.52) YoY

Valion Bio Inc - Q1 2026 Net Loss $2.23 per Share

THOMSON REUTERS

Valion Bio schedules first-quarter financial results release and conference call

Valion Bio subsidiary Velocity Bioworks opens biomanufacturing facility in San Antonio

Valion Bio receives first study protocol under agreement with NIAID

Valion Bio says NIAID funds up to $7 million Entolimod BLA-enabling studies under FDA Animal Rule

Valion Bio Receives First FDA-Precedent Study Protocol From Niaid for Entolimod™; Federal Agency to Fully Fund Bla-Enabling in Vivo Program and Co-Navigate FDA Submission

THOMSON REUTERS

Valion Bio Inc - Niaid to Fully Fund up to $7 Mln in Vivo Studies for Entolimod Bla

THOMSON REUTERS

Valion Bio appoints Melinda Lackey general counsel, SVP legal affairs

Valion Bio files Form 3 for General Counsel, SVP Legal Melinda Lackey

Press Release: Valion Bio Appoints Melinda Lackey as General Counsel

Tivic Health Systems (TIVC) Stock Surges Over 24% After Hours: Here's What Is Happening

Benzinga_recent_news

Tivic Health Systems rebrands as Valion Bio, ticker changes to VBIO

Tivic Health Systems Inc - to Rebrand as Valion Bio, Ticker to Vbio Effective April 28, 2026

THOMSON REUTERS

Top Tivic Health Systems Insider Makes Bold New Move With Fresh Stock Purchase

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/VBIO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VBIO\",,,,,undefined,":{"symbol":"VBIO","market":"US","secType":"STK","nameCN":"Valion Bio Inc","latestPrice":0.88,"timestamp":1778875200000,"preClose":0.9309,"halted":0,"volume":368568,"hourTrading":{"tag":"盘后","latestPrice":0.89,"preClose":0.88,"latestTime":"19:59 EDT","volume":1869,"amount":1680.1068,"timestamp":1778889587805,"change":0.01,"changeRate":0.011364,"amplitude":0.051136},"delay":0,"changeRate":-0.054678268342464226,"floatShares":2777300,"shares":3139095,"eps":-7.683047,"marketStatus":"Market Closed","change":-0.0509,"latestTime":"05-15 16:00:00 EDT","open":0.97,"high":1.06,"low":0.8546,"amount":353034.4067856,"amplitude":0.220647,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.683047,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779091200000},"marketStatusCode":7,"adr":0,"listingDate":1636606800000,"exchange":"NASDAQ","adjPreClose":0.9309,"preHourTrading":{"tag":"盘前","latestPrice":0.959,"preClose":0.9309,"latestTime":"09:20 EDT","volume":8956,"amount":8278.973866799999,"timestamp":1778851217872,"change":0.0281,"changeRate":0.030186,"amplitude":0.075196},"postHourTrading":{"tag":"盘后","latestPrice":0.89,"preClose":0.88,"latestTime":"19:59 EDT","volume":1869,"amount":1680.1068,"timestamp":1778889587805,"change":0.01,"changeRate":0.011364,"amplitude":0.051136},"volumeRatio":2.009379269875749},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VBIO\",,,,,undefined,":{"symbol":"VBIO","floatShares":2777300,"roa":"-28.69%","roe":"-82.69%","lyrEps":-19.678463,"volumeRatio":2.009379269875749,"shares":3139095,"dividePrice":0,"high":1.06,"amplitude":0.220647,"preClose":0.9309,"low":0.8546,"week52Low":0.721683,"pbRate":"0.16","week52High":5.6,"institutionHeld":0,"latestPrice":0.88,"eps":-7.683047,"divideRate":0,"volume":368568,"delay":0,"ttmEps":-7.683047,"open":0.97,"prevYearClose":1.45,"prevWeekClose":0.96,"prevMonthClose":0.9798,"prevQuarterClose":0.8858,"fiveDayClose":0.96,"twentyDayClose":1.26,"sixtyDayClose":0.8153},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VBIO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VBIO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VBIO","date":"2026-05-15","current":-0.114538,"percent":0.636364,"low":-0.392475,"twenty":-0.341701,"median":-0.33551,"eighty":-0.327405,"high":-0.298231,"avg":-0.338856,"sd":0.026132,"marketCap":2922183},"quantilePoints":[{"date":"2026-04-30","current":-0.311197,"twenty":-0.324163,"median":-0.319301,"eighty":-0.314439,"marketCap":2762808},{"date":"2026-05-08","current":-0.33713,"twenty":-0.336482,"median":-0.327405,"eighty":-0.314439,"marketCap":2993043},{"date":"2026-05-15","current":-0.329149,"twenty":-0.341701,"median":-0.33551,"eighty":-0.327405,"marketCap":2922183}],"updateTime":1778975421592},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VBIO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635273724","title":"Valion Bio’s Velocity Bioworks licenses LarmorBio’s BioScan-NMR platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2635273724","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635273724?lang=en_us&edition=fundamental","pubTime":"2026-05-15 06:26","pubTimestamp":1778797588,"startTime":"0","endTime":"0","summary":"Valion Bio’s (VBIO) wholly owned subsidiary, Velocity Bioworks, has entered into an exclusive commercial development and license agreement with Lar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/valion-bios-velocity-bioworks-licenses-larmorbios-bioscan-nmr-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/valion-bios-velocity-bioworks-licenses-larmorbios-bioscan-nmr-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4082","VBIO","NMR","BK4552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635573721","title":"Valion Bio Q1 net loss widens to $6.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635573721","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635573721?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:30","pubTimestamp":1778794252,"startTime":"0","endTime":"0","summary":"Valion Bio posted a net loss of USD 6.2 million for quarter ended March 31, 2026, widening from a net loss of USD 1.5 million a year earlier.Operating loss widened to USD 5.63 million as total operating expenses climbed to USD 5.63 million, led by research and development expense of USD 1.85 million and selling, general and administrative costs of USD 3.78 million.Cash and cash equivalents were USD 7.2 million at March 31, 2026, with cash used in operating activities of USD 5.01 million during the quarter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL1LZJGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635260877","title":"BRIEF-Valion Bio Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635260877","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635260877?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:52","pubTimestamp":1778791970,"startTime":"0","endTime":"0","summary":"BRIEF-Valion Bio Reports First Quarter 2026 Financial ResultsMay 14 (Reuters) - Valion Bio Inc VBIO.O:VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTSVALION BIO INC - Q1 2026 NET LOSS $2.23 PER","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA8JZZ6N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635723211","title":"Valion Bio Q1 EPS $(2.23) Up From $(2.52) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2635723211","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635723211?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:08","pubTimestamp":1778789328,"startTime":"0","endTime":"0","summary":"Valion Bio (NASDAQ:VBIO) reported quarterly losses of $(2.23) per share. This is a 11.51 percent increase over losses of $(2.52) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52579929/valion-bio-q1-eps-2-23-up-from-2-52-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Valion Bio Q1 EPS $(2.23) Up From $(2.52) YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTEC","NVIW.SI","NDX","TECS","GPIQ","QQQE","TQQQ","SQQQ","QQQM","IYW",".IXIC","QQQ","QQQJ","PSQ","QYLG","QDTE","QLD","MNQmain","JEPQ","TQQY","NQmain","VBIO","QQQY","QQQA","QID","ONEQ","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635726916","title":"Valion Bio Inc - Q1 2026 Net Loss $2.23 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2635726916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635726916?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA8JZZ6N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634286749","title":"Valion Bio schedules first-quarter financial results release and conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2634286749","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634286749?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:06","pubTimestamp":1778501206,"startTime":"0","endTime":"0","summary":"Valion Bio will report first-quarter 2026 financial results May 14, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDLb3KspN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633382201","title":"Valion Bio subsidiary Velocity Bioworks opens biomanufacturing facility in San Antonio","url":"https://stock-news.laohu8.com/highlight/detail?id=2633382201","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633382201?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:11","pubTimestamp":1778069476,"startTime":"0","endTime":"0","summary":"Valion Bio opened Velocity Bioworks biomanufacturing facility in San Antonio, activating wholly owned subsidiary as core of vertically integrated domestic production for Entolimod.Velocity Bioworks employs about 45 staff, completed tech transfer of Entolimod process, started incremental scale-up to support GMP manufacturing.Facility positions unit to supply Entolimod for potential US Strategic National Stockpile use under FDA Animal Rule pathway.Velocity Bioworks also begins operating as CDMO for third-party biologics clients alongside internal manufacturing role.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL4zgtCf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633948376","title":"Valion Bio receives first study protocol under agreement with NIAID","url":"https://stock-news.laohu8.com/highlight/detail?id=2633948376","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633948376?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:15","pubTimestamp":1777983318,"startTime":"0","endTime":"0","summary":"Valion Bio (VBIO) announced it has received the first study protocol under its previously announced non-clinical evaluation agreement with the Nati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/valion-bio-receives-first-study-protocol-under-agreement-with-niaid-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/valion-bio-receives-first-study-protocol-under-agreement-with-niaid-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633910577","title":"Valion Bio says NIAID funds up to $7 million Entolimod BLA-enabling studies under FDA Animal Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2633910577","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633910577?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:03","pubTimestamp":1777982591,"startTime":"0","endTime":"0","summary":"NIAID to fully fund up to USD 7 million of in vivo studies to support Entolimod BLA filing under FDA Animal Rule pathway.Program uses an FDA-precedent study protocol previously accepted for an acute radiation syndrome countermeasure, cutting design risk for BLA-enabling work.Studies to be run at Armed Forces Radiobiology Research Institute, with NIAID set to co-navigate FDA submission upon favorable results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via PR Newswire  on May 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL397Rwx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633359910","title":"Valion Bio Receives First FDA-Precedent Study Protocol From Niaid for Entolimod™; Federal Agency to Fully Fund Bla-Enabling in Vivo Program and Co-Navigate FDA Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2633359910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633359910?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:00","pubTimestamp":1777982418,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUA66QTZY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633106339","title":"Valion Bio Inc - Niaid to Fully Fund up to $7 Mln in Vivo Studies for Entolimod Bla","url":"https://stock-news.laohu8.com/highlight/detail?id=2633106339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633106339?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:00","pubTimestamp":1777982418,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUA66QTZY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633107965","title":"Valion Bio appoints Melinda Lackey general counsel, SVP legal affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2633107965","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633107965?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:13","pubTimestamp":1777925600,"startTime":"0","endTime":"0","summary":"Valion Bio named Melinda Lackey general counsel, senior vice president of legal affairs.Lackey joins from Alaunos Therapeutics, where she served as senior vice president of legal and administration.Earlier roles include senior legal counsel at Kuur Therapeutics, associate positions at Winston & Strawn, Howrey, research posts at University of Texas Health Science Center at Houston, UT MD Anderson Cancer Center.Move comes as company advances Entolimod toward an FDA Animal Rule pathway for acute radiation syndrome, scales CDMO unit Velocity Bioworks in San Antonio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL2twWmv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VBIO","BK4082","TCRT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633965305","title":"Valion Bio files Form 3 for General Counsel, SVP Legal Melinda Lackey","url":"https://stock-news.laohu8.com/highlight/detail?id=2633965305","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633965305?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:08","pubTimestamp":1777925294,"startTime":"0","endTime":"0","summary":"Valion Bio filed an initial beneficial ownership statement naming Melinda Lackey as general counsel and SVP of legal, dated May 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL1ngBkJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBIO","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633047963","title":"Press Release: Valion Bio Appoints Melinda Lackey as General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2633047963","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633047963?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:05","pubTimestamp":1777925100,"startTime":"0","endTime":"0","summary":"Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership Team. SAN ANTONIO, May 4, 2026 /PRNewswire/ -- Valion Bio, Inc.  , a clinical-stage immunotherapeutics company developing Entolimod for Acute Radiation Syndrome  and oncology supportive care, today announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. Ms. Lackey brings nearly two decades of combined scientific and legal experience across clinical-stage biopharmaceutical development, intellectual property strategy, and Nasdaq public company governance, a profile built for Valion Bio's current phase of growth.\"Melinda's appointment reflects Valion Bio's direction. She has built her career at the intersection of cutting-edge immunotherapy and the legal strategy that protects it, from the bench at MD Anderson to senior legal leadership at a Nasdaq-listed cell therapy company. As we work to execute our capital raise, adv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","TM","BK4588","BK4082","BK4585","BK4139","CDMO","BK4099","VBIO","03160","NQmain","BK4604","TCRT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629981909","title":"Tivic Health Systems (TIVC) Stock Surges Over 24% After Hours: Here's What Is Happening","url":"https://stock-news.laohu8.com/highlight/detail?id=2629981909","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629981909?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:17","pubTimestamp":1777018620,"startTime":"0","endTime":"0","summary":"Tivic Health Systems Inc. shares rise 24.10% after hours after announcing a full rebrand to Valion Bio and a strategic pivot toward Entolimod-based immunotherapy development.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/24/A-Close-up--Blurred-View-Of-A-Digital-Sc.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/24/A-Close-up--Blurred-View-Of-A-Digital-Sc.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/04/52022779/tivic-health-systems-tivc-stock-surges-over-24-after-hours-heres-what-is-happening","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/04/52022779/tivic-health-systems-tivc-stock-surges-over-24-after-hours-heres-what-is-happening","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4082","BK4150","VBIO","RSI","TIVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629669868","title":"Tivic Health Systems rebrands as Valion Bio, ticker changes to VBIO","url":"https://stock-news.laohu8.com/highlight/detail?id=2629669868","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629669868?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:13","pubTimestamp":1776975207,"startTime":"0","endTime":"0","summary":"Nasdaq ticker will change to VBIO from TIVC.Rebrand aligns with shift to late-stage biopharmaceutical focus centered on Entolimod, a candidate for Acute Radiation Syndrome under FDA Animal Rule pathway.Program targets potential BARDA-backed procurement for U.S. Strategic National Stockpile, positioned as non-dilutive revenue opportunity.Velocity Bioworks unit, acquired for about $16.3 million, is positioned to support Entolimod supply while building third-party CDMO revenue.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL7Qnlnn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","TIVC","VBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629850231","title":"Tivic Health Systems Inc - to Rebrand as Valion Bio, Ticker to Vbio Effective April 28, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629850231","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629850231?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:05","pubTimestamp":1776974737,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nFWN41616K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","VBIO","TIVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629094703","title":"Top Tivic Health Systems Insider Makes Bold New Move With Fresh Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2629094703","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629094703?lang=en_us&edition=fundamental","pubTime":"2026-04-21 10:01","pubTimestamp":1776736902,"startTime":"0","endTime":"0","summary":"New insider activity at Tivic Health Systems ( ($TIVC) ) has taken place on April 20, 2026. Director Sheryle Bolton has boosted her stake in Tivic ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-tivic-health-systems-insider-makes-bold-new-move-with-fresh-stock-purchase-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-tivic-health-systems-insider-makes-bold-new-move-with-fresh-stock-purchase-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","VBIO","TIVC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}